Key result
COVID-19 is linked to ~10-fold higher mortality in patients with rising high-sensitivity troponin.
Why the study?
The high fatality rate and cardiovascular complications in patients with COVID-19, especially those with heart disease and hypertension, necessitate summarizing current evidence on COVID-19-associated cardiac injury and its diagnosis and treatment.
This review highlights the significant cardiovascular implications of COVID-19, including high fatality rates in patients with pre-existing heart disease and the frequent occurrence of acute cardiac injury and arrhythmias.
May warrant enhanced cardiac monitoring in COVID-19 with comorbidities; leaves open causal mechanisms and targeted interventions.
Since the outbreak of COVID-19 or coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 from Wuhan, China, the cardiology fraternity's interest has been drawn towards the pandemic with a high case fatality rate of 10.5% and 6% in patients with heart disease and hypertension, respectively. One of the postulated mechanisms for this high fatality rate is the possible abundance of ACE type 2 receptor in the cardiovascular system that strongly binds with the spike protein of COVID-19 and helps internalise into the cell resulting in acute cardiac injury (ACI). More than 7% of cases with COVID-19 are reported to have this type of ACI. A tenfold rise in mortality has been observed in patients with COVID-19 who experience a rise in high-sensitivity (hs)-troponin. All most half of the patients who died of COVID-19 had a rise in hs-troponin. More than 15% of cases with COVID-19 experienced different types of arrhythmias. All these statistics denote how important cardiovascular pathology is in patients with COVID-19. Controversies of renin-angiotensin-aldosterone system inhibitors usage in patients with COVID-19 and meticulous handling of case with acute coronary syndrome categorically stresses cardiologists to bust the myths hovering around and set a standard guideline to counterfeit the fatality with timely diagnosis and treatment of COVID-19-induced ACI. In this review, we sought to summarise the current evidence of COVID-19-associated cardiac injury and suggest the implications for its proper diagnosis and treatment.
No takes yet. Share an insight, caveat, or question.
Shaha et al. (2021) conducted a review in COVID-19 and cardiac injury. COVID-19 was evaluated. COVID-19 is associated with acute cardiac injury in over 7% of cases and a tenfold increase in mortality among patients who experience a rise in high-sensitivity troponin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: